Aurobindo Pharma’s arm restarts distribution of aseptic products manufactured at Unit III

13 Mar 2024 Evaluate

Aurobindo Pharma’s wholly owned subsidiary-- Eugia Pharma Specialities has started distribution of aseptic products manufactured at Unit III, that was temporarily stopped. The company also expects to start commercial production from the aseptic lines of the said facility in a phased manner beginning next week and to re-start all the lines by April 15, 2024.

Earlier, Eugia Pharma Specialities had restarted production in its terminally sterilized product lines at its Unit-III. The production was temporarily stopped to address some of the observations of United States Food and Drug Administration (USFDA) in their recent inspection concluded on February 2, 2024. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1220.20 -27.70 (-2.22%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.